REG - Physiomics PLC - Appointment of Independent Non-Executive Director

PhysiomicsAnnouncement

01/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220901:nRSA7414Xa&default-theme=true

RNS Number : 7414X  Physiomics PLC  01 September 2022

1 September 2022

 

Physiomics plc

("Physiomics") or ("the Company")

 

Physiomics appoints new Independent Non-Executive Director

 

Physiomics plc (AIM: PYC), the consultancy using mathematical models to
support the development of drug treatment regimens and personalised medicine
solutions, is pleased to announce that Mr Shalabh Kumar has joined the
Company's board as an Independent Non-Executive Director with immediate
effect.

Mr Shalabh Kumar is a proven business executive with over 30 years of
experience within the life sciences consulting and services industry. Shalabh
co-founded, and subsequently was the Chief Executive Officer of Kinapse, a
life sciences consulting and outsourcing service provider, which was later
acquired by Syneos Health® (Nasdaq: SYNH) after growing to employ over 600
people across UK, India and US. Prior to that, he worked for Accenture,
Gillette (Procter & Gamble) and Unilever. More recently, Shalabh has been
working as an independent strategy consultant and angel investor in the life
sciences industry, working with biopharmaceutical companies, life sciences
services and technology companies and private equity firms. Mr Kumar's recent
roles include Chairman of the Board of Clustermarket Ltd, a lab software
start-up; independent strategy consultant to the life sciences R&D group
of Accenture plc (NYSE: ACN); and Global Head of Services at Navitas Life
Sciences, a technology-backed life sciences contract research organisation.

Dr Jim Millen, CEO, commented: "On behalf of the board of Physiomics, we are
delighted that Shalabh has agreed to join the Company as an Independent
Non-Executive Director. Shalabh has impressive business acumen within the life
sciences sector and has overseen the successful implementation of growth
strategies at a number of companies. We look forward to working alongside
Shalabh in the future and welcome the insight he can provide to Physiomics."

Further information on Shalabh Kumar's appointment:

The following details in relation to the appointment of Mr Shalabh Kumar are
disclosed in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules:

Shalabh Kumar (aged 55) has held the following directorships in the past five
years.

 Current Directorships / Partnerships  Past Directorships / Partnerships (last five years)
 Karmic Wheel Consulting Limited       Clustermarket Ltd
 Pharmalancers Limited

 

 

 

 

There is no further information to be disclosed in relation to Shalabh Kumar's
appointment pursuant to AIM Rule 17 or Schedule Two, paragraph (g) (i)-(viii)
of the AIM Rules for Companies.

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFIFITTVILVIF